ENPEP-Targeted Drug Discovery Services

Introduction

Glutamyl aminopeptidase is also known as CD249. It is encoded by the ENPEP gene in humans. This gene encodes glutamyl aminopeptidase, a type II integral membrane protein with an extracellular zinc-binding domain. This protein can upregulate blood pressure by cleaving the N-terminal aspartate from angiotensin II and can regulate blood vessel formation and enhance tumorigenesis in some tissues. Along with ANPEP and DPP4, ENPEP was found to be a candidate co-receptor for the coronavirus SARS-CoV-2, which causes COVID-19. [provided by RefSeq, Apr 2020] Previous studies indicated that ENPEP contributes to the development of the immune system and it is also associated with the development of cancer, such as breast cancer, leukemia, and renal cancer.

Direction of Drugs Discovery

• ENPEP Inhibitor
• Developing New Clinical Effects on ENPEP from Existing Drugs

Drugs

• ENPEP Inhibitor- PMID10602705C40, KELATORPHAN, EC33, QGC-001

What We Offer

Target Testing

CD BioSciences provides ENPEP testing services by pep-ELISA, WB, IF, IP, ICC, or IHC assay. The results of ENPEP testing are used to evaluate the activities of candidates against ENPEP or targeted diseases. You can choose one or more testing ways to detect the level of ENPEP according to your experiment.

Hit Identification (show more)

The goal of early drug discovery is to find novel lead compounds that have the desired potency, selectivity, and ADMET properties for pre-clinical evaluation.
CD BioSciences offers hit identification services to make your finding of targeted compounds more successful and faster.
• High-Throughput Screening
• ENPEP-Targeted in Silico Virtual Screening
• Fragment-Based Screening
• High-Content Screening

Antibody Drugs Development Services (show more)

Antibody drugs exhibit many incomparable advantages, such as high specificity, affinity, and efficiency, which is an emerging direction on targeted drug development. CD BioSciences provides comprehensive services on ENPEP-targeted antibody drugs development with professional technology, extensive experience, and advanced equipment.
• Antibody Preparation Services
• Phage Display Services
• Antibody-Drug Conjugates
• Bispecific Antibody Services
• Antibody Humanization Services

Pharmacological Experiments (show more)

We will create a specific experimental plan according to your requirements, including but not limited to
• Pharmacokinetics / Pharmacodynamics
• Pharmacodynamics
• Pharmacokinetics
• Safety Pharmacology

Disease Models Screening (show more)

We will create specific disease models to accelerate your targeted drug discovery project, including but not limited to
• Cancers—Choriocarcinoma. (show more)
CD BioSciences will establish the specific disease models according to your requirements to evaluate the inhibitory activity of your candidates targeted ENPEP. We have various cell lines and the species of our animal models cover rats, mice, rabbits, dogs, and non-human primates.

Inquire Us

References

1. Stelzer G.; et al. The GeneCards Suite: From Gene Data Mining to Disease Genome Sequence Analysis, Current Protocols in Bioinformatics (2016), 54:1.30.1 - 1.30.33.doi: 10.1002 / cpbi.5.
2. Wishart DS; et al. DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue): D901-6.
3. Y. Zhou; et al. Therapeutic target database update 2022: facilitating drug discovery with enriched comparative data of targeted agents. Nucleic Acids Research. 50(D1): 1398-1407 (2022). PMID: 34718904.
4. Wang, A., et al., Enpep as a potential predictor of immune checkpoint inhibitor efficacy. Cancer Med, 2022. 11(3): p. 880-887.